🧬 Longevity
Semaglutide Dissolves 23 Pounds in 26 Weeks. Eight of Those Pounds Are Muscle. Four Companies Are Racing to Fix the Ratio.
A 2024 Lancet Diabetes & Endocrinology meta-analysis found that 25-39% of weight lost on GLP-1 drugs is lean mass, not fat. Three pharmaceutical companies just reported Phase 2b data on different molecular strategies to preserve muscle while patients lose weight. A head-to-head comparison of all four approaches, which no publication has assembled, reveals that the most effective solution might be the cheapest one.
34.5%. That is the fraction of weight loss attributable to lean mass in the semaglutide-only arm of Regeneron's COURAGE trial, a 999-patient Phase 2b study whose interim results arrived in mid-2025. Patients on semaglutide shed an average of 23 pounds in 26 weeks. Roughly eight of those pounds were not fat. They were muscle, bone mineral density, organ tissue, and water bound to protein structures that the body dismantled because the drug suppressed appetite so thoroughly that the caloric deficit exceeded what fat stores alone could cover.
This is not a side effect. It is the central pharmacological tradeoff of the most commercially successful drug class in pharmaceutical history, a class that generated over $40 billion in U.S. prescription spending in 2024 alone and whose patient population has grown from roughly 9 million semaglutide prescriptions in 2022 to an estimated 15-20 million Americans across all GLP-1 formulations by early 2026, according to IQVIA dispensing data and AJMC reporting on tirzepatide's rapid uptake.
In a November 2025 survey of physicians on the Sermo platform, 63% reported observing muscle loss in their GLP-1 patients. Not all of them thought it was a problem.
Now three separate Phase 2b trials have produced data on pharmacological strategies to change the ratio, each attacking a different molecular target. Combined with the oldest intervention of all, resistance training, the comparison reveals four distinct bets on how to solve a problem that did not exist before 2021.
Approach 1: Block Myostatin (Regeneron)
Regeneron's strategy targets GDF8, commonly called myostatin, a protein the body produces specifically to limit muscle growth. Block myostatin and muscles grow larger, or at minimum resist shrinking during caloric deficit. Regeneron's antibody, trevogrumab, does exactly this, and a second antibody called garetosmab blocks activin A, another muscle growth inhibitor. Across 999 patients with obesity, COURAGE tested semaglutide alone, semaglutide plus trevogrumab at two doses, and a triplet combining all three drugs.
Doublet results were modest: roughly 51% of lost weight came from fat rather than lean tissue in both dose arms, an improvement but not a transformation. Triplet results were dramatic: 80.9% of lean mass was preserved and fat loss exceeded semaglutide monotherapy by 27.3%.
It also nearly killed some patients. Treatment-emergent adverse events hit 77.2% in the triplet arm versus 64.9% on semaglutide alone, with severe events jumping from 2% to 10.1%. More than one in four patients stopped taking the drugs before the trial's midpoint, a discontinuation rate of 28.3%. Two patients in the triplet arm died: one from cardiac arrest with a pre-existing cardiovascular history, one from an unknown cause in a patient with multiple cardiovascular risk factors, though Regeneron stated no causal link was established. All data is interim, covering approximately half of enrolled patients at 26 weeks.
Approach 2: Block the Activin Receptor (Eli Lilly / Versanis)
Bimagrumab takes a broader approach. Instead of blocking one specific growth inhibitor, it blocks the type II activin receptor (ActRII) itself, which is the docking station where multiple muscle-suppressing signals converge, including myostatin, activin A, and GDF11. Versanis Bio developed the antibody before Eli Lilly acquired the company, and the BELIEVE trial tested it alongside semaglutide in 507 patients over 72 weeks.
92.8% of all weight lost was fat mass. Total weight loss hit 22.1%, comparable to semaglutide's best monotherapy numbers, but the composition of that loss was radically different from what semaglutide achieves alone. Where semaglutide patients typically lose a third of their weight as muscle, bimagrumab-semaglutide patients lost barely 7% as lean tissue. Safety data, presented at the American Diabetes Association's 2025 Scientific Sessions and published in Nature Medicine, showed adverse event rates consistent with each drug's known profile, with no deaths reported in any arm.
Seventy-two weeks of data gives BELIEVE the longest follow-up window of the three pharmacological trials, and it also used the broadest patient population. These are not small advantages when the FDA evaluates Phase 3 design.
Approach 3: Activate Androgen Receptors (Veru)
Enobosarm is a selective androgen receptor modulator, a SARM, which means it mimics the muscle-building effects of testosterone without most of the hormonal side effects that make actual testosterone a blunt instrument for clinical use. Veru's QUALITY trial enrolled 168 older adults, a deliberate focus on the population most vulnerable to sarcopenia, the age-related muscle wasting that precedes falls, fractures, nursing home admission, and death.
At the 3mg dose, enobosarm plus semaglutide produced extraordinary selectivity: 99.1% of weight lost was fat mass. Lean mass loss dropped by 71% compared to semaglutide plus placebo. Fat loss actually increased by 27%. Patients on the combination also showed fewer gastrointestinal side effects than those on semaglutide alone, which matters because nausea and vomiting are the primary reasons patients discontinue GLP-1 therapy.
Veru reported one additional finding that none of the other trials addressed. In the maintenance extension study, patients who discontinued semaglutide after treatment regained 46% less weight if they had been on enobosarm, and they regained zero fat mass. Veru has requested an End of Phase 2 meeting with the FDA to discuss Phase 3 trial design.
Sample size is QUALITY's major limitation. 168 patients is sufficient for a Phase 2b signal but provides far less statistical power than COURAGE's 999 or BELIEVE's 507. Its older adult focus, while scientifically targeted, means the results may not generalize to the broader GLP-1 population.
Approach 4: Lift Heavy Things
A 2024 study in The Lancet Regional Health found that progressive resistance training during GLP-1 therapy preserves lean mass without any additional drugs, additional costs, or additional risks.
It costs a gym membership. It works. Almost nobody does it.
In the Sermo physician survey, physicians cited a consistent pattern: patients on GLP-1 drugs treat the medication as a replacement for exercise and dietary modification rather than a complement to them. This behavioral reality does not appear in any clinical trial protocol because trials mandate dietary counseling and often encourage physical activity as part of the treatment regimen. But the real-world GLP-1 population, the one generating those 15-20 million prescriptions, is not living inside a clinical trial.
The Comparison Nobody Has Published
| Dimension | Regeneron (COURAGE) | Eli Lilly (BELIEVE) | Veru (QUALITY) | Resistance Training |
|---|---|---|---|---|
| Mechanism | Anti-myostatin ± anti-activin A | Anti-ActRII receptor | SARM (androgen receptor) | Mechanical loading |
| Trial size | 999 | 507 | 168 | Meta-analyses |
| Fat selectivity | 80.9% (triplet) | 92.8% | 99.1% (3mg) | Variable |
| Safety signal | 2 deaths, 28.3% dropout | Clean | Clean; fewer GI AEs | Zero pharmacological risk |
| Duration | 26 weeks (interim) | 72 weeks | 16 weeks + extension | Lifelong |
| Delivery | Injection (antibody) | Injection (antibody) | Oral pill | Barbells |
| Estimated cost | $10,000-30,000/yr (antibody pricing) | $10,000-30,000/yr | Lower (small molecule) | $0-600/yr |
| Weight regain data | Not tested | Not tested | 46% less regain | Literature supports |
Read the table from right to left and something uncomfortable emerges: the cheapest, safest, most durable intervention with zero dropout risk already exists and requires no FDA approval. In essence, all three pharmaceutical approaches are building molecular substitutes for exercise in patients who are not exercising.
Original Calculation: What 135 Million Pounds of Lost Muscle Means
If 15 million Americans are taking GLP-1 drugs and losing an average of 30 pounds over a year of treatment (a conservative midpoint between semaglutide and tirzepatide trial data), and 30% of that weight loss is lean mass, the collective lean mass loss across the GLP-1 population is approximately 135 million pounds. Each pound of skeletal muscle burns roughly 6 to 10 calories per day at rest, according to metabolic research published in the Journal of Clinical Investigation. At the midpoint of 7 calories per pound, that represents approximately 945 million fewer calories burned daily across the GLP-1 population, equivalent to removing the basal metabolic contribution of about 475,000 fully muscled adults from the national energy balance.
This calculation is approximate. It assumes the full GLP-1 patient population is actively losing weight (many are in maintenance), uses midpoint estimates for both weight loss and lean mass fraction, and treats skeletal muscle as the dominant component of lean mass loss. The real number could be substantially lower. It could also be higher. The inputs matter less than the direction: at population scale, pharmacologically accelerated muscle loss is not a rounding error.
The Strongest Case That This Doesn't Matter
The SEMALEAN study, a real-world investigation of 106 patients with severe obesity on semaglutide 2.4mg, found that sarcopenic obesity prevalence actually decreased from 49% to 33% at 12 months. Patients lost lean mass in absolute terms but gained muscle function. Grip strength, gait speed, and overall physical performance improved because the patients were carrying less total load. The body may have been shedding structural tissue that existed primarily to support 300-pound frames, not functional muscle that a 220-pound person needs.
This is the strongest counterargument to the muscle loss alarm. If the lean mass being lost is scaffolding rather than engine, the absolute number overstates the clinical significance. A 2026 review in Nature Reviews Endocrinology titled "Causes of sarcopenia and frailty in people taking GLP1RAs" examined animal and human data and found no definitive evidence that GLP-1 drugs cause disproportionate muscle loss relative to the magnitude of caloric restriction they induce. The drugs do not seem to target muscle. They restrict calories. Caloric restriction always costs some lean mass. That is physics, not pharmacology.
What this argument does not address is the 70-year-old patient who starts semaglutide with borderline muscle mass and crosses below the sarcopenia threshold during treatment. For that patient, the distinction between "proportionate caloric restriction effect" and "functionally dangerous muscle loss" is academic. The fall happens either way.
What We Did Not Prove
These three trials cannot be directly compared. They enrolled different patient populations, measured different primary endpoints over different timeframes, and reported interim versus final data at different stages of completion. The COURAGE trial's 26-week interim data may look materially different at 52 weeks. The QUALITY trial's 168-patient sample is powered for signal detection, not for the kind of subgroup analysis that Phase 3 trials require. The BELIEVE trial's 72-week data is the most mature but was conducted before tirzepatide overtook semaglutide as the dominant GLP-1 prescription, meaning its results may not translate to the current drug landscape.
The estimated cost column in the comparison table uses antibody pricing analogies and has not been confirmed by any of the three companies. Small-molecule oral drugs (enobosarm) are generally cheaper to manufacture than monoclonal antibodies, but pricing in obesity medicine reflects market positioning, not manufacturing cost. None of these drugs has an approved price.
What You Can Do
If you are currently taking semaglutide, tirzepatide, or any GLP-1 receptor agonist, the single most evidence-supported action is resistance training twice per week, targeting major muscle groups with progressive overload. A 2026 PubMed review of muscle health during incretin therapy specifically recommends this alongside protein intake of 1.2 to 1.6 grams per kilogram of body weight per day. Ask your physician for a referral to a physical therapist or certified strength and conditioning specialist who understands pharmacological weight loss. Do not wait for any of these three drugs to reach the market. Two of them are injected antibodies that will likely cost more than your GLP-1 prescription, and none will complete Phase 3 before 2028 at the earliest.
If you are a physician prescribing GLP-1 drugs, measure body composition at baseline and every 12 weeks using dual-energy X-ray absorptiometry (DEXA) if available, or at minimum track grip strength with a hand dynamometer. Grip strength below 26 kg for men or 18 kg for women indicates sarcopenia risk per the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Patients over 60 deserve particular monitoring because they start closer to the threshold.
If you are evaluating these three companies as investments, watch the FDA's response to Veru's End of Phase 2 meeting request. Enobosarm's oral delivery, clean safety profile, weight regain prevention data, and lower projected manufacturing cost give it a structural advantage in market access, even though BELIEVE's 72-week dataset and Eli Lilly's distribution infrastructure make bimagrumab the more likely first-to-market candidate. Regeneron's triplet therapy has the strongest efficacy data and the most concerning safety data. Phase 3 design will determine whether the deaths in the triplet arm are treated as a red flag or a statistical artifact.
Bottom Line
The GLP-1 revolution solved the hardest problem in obesity medicine: making people lose weight reliably and sustainably. In doing so, it created a new problem. A third of what patients lose is the tissue that keeps them upright, keeps their bones from breaking, and burns calories at rest so the weight stays off. Three pharmaceutical companies spent hundreds of millions of dollars to produce Phase 2b evidence that pharmacology can fix what pharmacology broke. The data ranges from impressive (Veru's 99.1% fat selectivity) to concerning (Regeneron's two deaths) to cautiously promising (Lilly's 72-week safety record). A barbell and 120 grams of protein accomplish much of the same goal for the cost of groceries and discomfort. The pharmaceutical industry is betting that most patients will pay for a pill before they pick up a weight. Based on two decades of behavioral data in obesity medicine, that bet is probably correct.